Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
26.76 EUR | +0.30% | -2.12% | -27.66% |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company appears to be poorly valued given its net asset value.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.66% | 1.88B | B | ||
+2.17% | 42.75B | B | ||
+47.64% | 41.61B | A | ||
+12.32% | 41.34B | B- | ||
-12.36% | 26.59B | C | ||
+8.28% | 25.49B | B- | ||
-23.21% | 18.12B | B | ||
+30.25% | 12.24B | C+ | ||
-1.32% | 11.76B | C+ | ||
+8.43% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GLPG Stock
- Ratings Galapagos NV